Novartis to buy pharmaceutical group AAA for US$3.9b
Zurich
NOVARTIS is buying French-based Advanced Accelerator Applications (AAA) for US$3.9 billion, giving the Swiss drugmaker a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.
The cash offer of US$41 per ordinary share and US$82 per American depositary share represents a 47 per cent premium to AAA's price before media reports on Sept 27 that Novartis was interested. The ADS closed on Friday at US$72.91 and were priced at only US$16 when they listed two years ago.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
KKR’s earnings rise 20% on strong management fees, annuities business
Stocks to watch: DBS, Olam, Parkway Life Reit, Japfa, CSE Global
Mastercard’s profit beats as consumer spending defies inflation worries
Google’s payments to Apple reached US$20 billion in 2022, antitrust court documents show
DBS Q1 profit up 15% to S$2.96 billion; interim dividend at S$0.54
Qualcomm forecast beats estimates as AI drives chip sales in China